Related Experiment Videos
New chemotherapy regimens for advanced bladder cancer
1Department of Medicine, University of Chicago, IL 60637, USA.
Seminars in Urologic Oncology
|March 21, 1998
Summary
Newer chemotherapy agents show promise for metastatic bladder cancer, offering similar response rates to the standard MVAC regimen but with reduced toxicity. Further randomized trials are needed to confirm these findings and advance treatment options.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) is the established standard chemotherapy for metastatic or unresectable bladder cancer.
- Despite its efficacy, MVAC has shown disappointing long-term outcomes, necessitating the exploration of alternative treatment strategies.
Purpose of the Study:
- To review the development and efficacy of newer chemotherapeutic agents and combination regimens for bladder cancer.
- To compare the response rates and toxicity profiles of novel agents against the standard MVAC regimen.
Main Methods:
- Review of randomized trials and recent reports on novel antifolates, gemcitabine, taxanes, ifosfamide, and gallium nitrate.
- Analysis of objective response rates, including complete responses, in both previously untreated and treated patients.
- Evaluation of toxicity data for newer combination regimens compared to MVAC.
Main Results:
- Individual novel agents and combination regimens demonstrate objective responses in bladder cancer patients.
- Emerging data suggest combination regimens achieve response rates comparable to MVAC.
- These newer regimens appear to be associated with significantly less toxicity than MVAC.
Conclusions:
- Novel agents and combination regimens represent a potential advancement in metastatic bladder cancer therapy.
- The reduced toxicity of newer regimens, if validated in randomized trials, could improve patient outcomes.
- Further confirmation through randomized trials is crucial to establish these newer approaches as superior to MVAC.